SUMMARY: U.S. stocks fluctuated but remained near record highs after the Federal Reserve cut its main interest rate for the first time this year. The Fed’s projections suggest two more cuts this year and another in 2026, initially boosting stocks before Fed Chair Jerome Powell cautioned that these are just projections amid uncertain conditions. The Fed faces a challenge balancing slowing job growth and persistent inflation, with inflation unlikely to drop below 2% soon. Smaller stocks surged briefly, led by Lyft and Workday gains, while Big Tech declined. International markets were mixed, with Japan’s exports to the U.S. falling sharply due to tariffs.

Read the full article

The post US stocks churn amid uncertainty about how many more rate cuts are coming from the Fed appeared first on www.wxxv25.com

SUMMARY: Since President Trump’s emergency law-and-order surge began last month in Washington, D.C., over 50 people have faced federal charges, but at least 11 cases have been dismissed, straining court resources. Judges criticize prosecutorial decisions as poorly vetted, with grand juries occasionally refusing indictments, indicating weak evidence. U.S. Magistrate Judge Matthew Sharbaugh warned that the strategy’s high dismissal rate has “real-world consequences.” Some serious charges, including assaults on federal agents, have collapsed or been downgraded to misdemeanors. U.S. Attorney Jeanine Pirro defends her office’s actions, citing evolving evidence, while critics argue the surge’s legal approach mishandles cases and tarnishes justice.

Read the full article

The post Prosecutors already have dropped nearly a dozen cases from Trump’s DC crime surge, judge says appeared first on www.wxxv25.com

SUMMARY: The FDA has targeted telehealth companies like Hims & Hers for promoting unofficial versions of prescription drugs, especially weight loss medications, with misleading advertising. The agency sent over 100 warning letters ordering removal of false claims that compounded drugs are equivalent to FDA-approved ones like Wegovy and Ozempic. This crackdown follows a Trump administration directive to ensure pharmaceutical ads are truthful and non-misleading. Hims, which offers customized compounded treatments, disputes being subject to traditional drug ad rules. The FDA also criticized AstraZeneca’s FluMist vaccine ad for downplaying side effects. Critics argue drug ads boost demand, sometimes causing inappropriate prescribing.

Read the full article

The post FDA takes aim at Hims and other telehealth services in drug advertising blitz appeared first on www.wxxv25.com